JP2006525288A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525288A5
JP2006525288A5 JP2006505607A JP2006505607A JP2006525288A5 JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5 JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5
Authority
JP
Japan
Prior art keywords
sequence
type
amino acid
information
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006505607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525288A (ja
Filing date
Publication date
Priority claimed from ES200301054A external-priority patent/ES2246105B1/es
Application filed filed Critical
Publication of JP2006525288A publication Critical patent/JP2006525288A/ja
Publication of JP2006525288A5 publication Critical patent/JP2006525288A5/ja
Pending legal-status Critical Current

Links

JP2006505607A 2003-05-08 2004-05-03 アルツハイマー病治療方法 Pending JP2006525288A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011191515A Division JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Division JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法

Publications (2)

Publication Number Publication Date
JP2006525288A JP2006525288A (ja) 2006-11-09
JP2006525288A5 true JP2006525288A5 (https=) 2007-02-08

Family

ID=32982086

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006505607A Pending JP2006525288A (ja) 2003-05-08 2004-05-03 アルツハイマー病治療方法
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Country Status (19)

Country Link
US (6) US20090162362A1 (https=)
EP (5) EP2305286A3 (https=)
JP (5) JP2006525288A (https=)
CN (2) CN1784240A (https=)
AT (1) ATE435024T1 (https=)
AU (2) AU2004237373A1 (https=)
BR (1) BRPI0410684A (https=)
CA (1) CA2524571C (https=)
CY (1) CY1109454T1 (https=)
DE (1) DE602004021797D1 (https=)
DK (3) DK2356996T5 (https=)
ES (6) ES2246105B1 (https=)
IL (8) IL171651A (https=)
MX (1) MXPA05010914A (https=)
PL (3) PL2075007T3 (https=)
PT (3) PT1623719E (https=)
RU (2) RU2385161C2 (https=)
SI (1) SI1623719T1 (https=)
WO (1) WO2004098631A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) * 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
RS53174B (sr) * 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011070174A1 (en) 2009-12-11 2011-06-16 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CA2805414C (en) * 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
RU2607368C2 (ru) * 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2340394A1 (en) * 1998-08-20 2000-03-02 Jorge R. Barrio Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Similar Documents

Publication Publication Date Title
JP2006525288A5 (https=)
JP2012530145A5 (https=)
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
NZ579566A (en) Modified fgf-21 polypeptides and their uses
RU2014131605A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
JP2004535461A5 (https=)
EP2386566A3 (en) Chi-conotoxin peptides (II)
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
EP4676509A2 (en) Rippled antiparallel cross-beta dimers and related materials, compositions and methods
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
RU2007119376A (ru) Тимус - специфический белок
ES2834125T3 (es) Síntesis de compuestos cíclicos peptidomiméticos de giro beta
Bitar The primary structure of the ribosomal protein L29 from Escherichia coli
Ilisz et al. High-performance liquid chromatography of biologically important, small epimeric peptides and their L, D-amino acid content
WO2001009174A3 (en) Plant defensin variants
JP2005501544A5 (https=)
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof
JP2003522184A5 (https=)
JP2009503092A5 (https=)
JP2002534996A5 (https=)
EP1572725A4 (en) NEW CHI-CONOTOXINPEPTIDE (-I)
Strumeyer The Amino Acids Found in Proteins
EP0361956A3 (en) Increased expression of small molecular weight recombinant proteins
JP2005527491A5 (https=)
AR009805A1 (es) Peptidos que contienen cisteina